Richter’s disease, more formally called Richter transformation or Richter syndrome, is a rare and serious complication in which chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) transforms into a fast-growing, aggressive lymphoma. It affects roughly 5% of people with CLL, and the shift can be dramatic: a cancer that may have been manageable for years suddenly behaves like a completely different disease, with survival often measured in months rather than years.1The American Journal of Surgical Pathology. IgVH Mutational Status and Clonality Analysis of Richter’s Transformation The condition remains one of the toughest challenges in blood cancer treatment, though new therapies are beginning to shift the landscape.
What Happens During the Transformation
CLL is typically a slow-growing leukemia. Many patients live with it for years, sometimes without needing treatment at all. In Richter transformation, the underlying CLL cells, or sometimes an entirely new cancerous clone, evolve into an aggressive B-cell lymphoma. The vast majority of these cases become diffuse large B-cell lymphoma (DLBCL), the same type of aggressive lymphoma that can arise on its own in people who never had CLL. In rare instances, the transformation takes the form of Hodgkin lymphoma instead.1The American Journal of Surgical Pathology. IgVH Mutational Status and Clonality Analysis of Richter’s Transformation
The distinction between these two subtypes matters a great deal for treatment and outlook. DLBCL-type Richter transformation is far more common and generally carries a much worse prognosis. The Hodgkin variant, while still serious, tends to respond better to established chemotherapy regimens and can have meaningfully longer survival.
Symptoms That Raise Suspicion
Because CLL patients already have an abnormal blood cancer, the challenge is recognizing when something fundamentally changes. Clinicians are taught to suspect Richter transformation when a CLL patient experiences a rapid clinical downturn that doesn’t fit the usual slow pace of the disease. The classic warning signs include fever without an obvious infection, sudden and disproportionate swelling of one group of lymph nodes compared to others, and a sharp spike in lactate dehydrogenase (LDH), a blood marker that reflects tissue damage and cell turnover.2Seminars in Oncology. Richter syndrome: pathogenesis and management
Other symptoms can include drenching night sweats, unintentional weight loss, rapidly worsening fatigue, and sometimes pain or fullness in the abdomen from an enlarging spleen. None of these are unique to Richter transformation on their own, but the pattern of sudden deterioration in someone with a previously stable or slowly progressing CLL is the key signal. If you have CLL and notice a sharp change in how you feel, especially unexplained fevers or a lymph node that grows quickly while others stay the same size, that warrants urgent attention from your hematologist.
How It Is Diagnosed
Suspecting Richter transformation is one thing; confirming it requires tissue. A biopsy of an affected lymph node or mass is the gold standard. Pathologists examine the tissue under a microscope to determine whether the cells have shifted from the small, slow-growing CLL pattern to the large, aggressive cells characteristic of DLBCL or, less commonly, the distinctive Reed-Sternberg cells of Hodgkin lymphoma.
PET/CT imaging plays an important supporting role. Because transformed tissue is metabolically far more active than typical CLL, it lights up intensely on a PET scan. In a series of patients with suspected transformation, PET/CT proved useful both for confirming the clinical suspicion and for pinpointing exactly which lymph node or mass to biopsy, which can spare patients from an unnecessary procedure at a less informative site.3Journal of Nuclear Medicine. Detection of Richter’s Transformation of Chronic Lymphocytic Leukemia by PET/CT That said, a hot spot on PET alone is not proof of transformation; infection, inflammation, and even progressive CLL itself can sometimes produce bright uptake. Biopsy remains essential.
What Causes the Transformation
In most cases, Richter transformation arises directly from the existing CLL clone. Researchers can confirm this by comparing the immunoglobulin gene rearrangements in the CLL cells and the aggressive lymphoma cells. When both carry the same rearrangement, the transformation is considered “clonally related,” meaning the original leukemia itself evolved into the more dangerous disease. In a minority of cases, the aggressive lymphoma carries a completely different gene rearrangement, suggesting it developed independently, almost as a second cancer arising in the same patient. This “clonally unrelated” group tends to have a better outcome.4PubMed Central. Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome
Several molecular features have been linked to a higher risk of transformation. TP53 mutations stand out as one of the most important. In one study of patients who developed Richter syndrome, TP53 mutations were found in 80% of cases, far exceeding the rate in patients whose CLL remained stable. Intriguingly, these mutations could be detected in circulating tumor DNA before the clinical signs of transformation appeared, raising the possibility that blood-based monitoring could someday provide early warning.5PubMed Central. TP53 mutation is a high-risk factor for Richter’s syndrome based on circulating tumor DNA – Section: Abstract / Results
Risk Factors at the Time of CLL Diagnosis
Not every CLL patient faces the same likelihood of Richter transformation. A number of features present at the time of initial CLL diagnosis can help stratify risk. A large study found that lymph node size of 3 cm or greater was one of the strongest independent predictors, along with expression of the protein CD38 on CLL cells, use of a specific antibody gene segment called IGHV4-39, and the absence of a common chromosomal deletion known as del(13q14).6PubMed. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome Advanced disease stage at diagnosis, unmutated IGHV genes, and complex chromosomal abnormalities add further risk.7PubMed Central. The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
What’s worth emphasizing is that the factors predicting Richter transformation are not simply the same factors that predict CLL getting worse in general. They represent a somewhat distinct biological profile, which suggests that the mechanisms driving transformation overlap with, but are not identical to, the mechanisms driving CLL progression. For patients and clinicians, this means that the features present at CLL diagnosis can already hint at which patients deserve closer monitoring for this particular complication.
Treatment With Conventional Chemoimmunotherapy
The treatment of DLBCL-type Richter transformation has historically been one of the most frustrating areas in hematology. Standard chemotherapy regimens, often adapted from those used in de novo DLBCL, produce disappointing results in this setting. In a large series of 130 patients treated with chemotherapy or chemoimmunotherapy, the overall response rate was only about 39%.8PubMed. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation Complete remission rates with chemoimmunotherapy hover around 20%, and fewer than one in five patients achieve long-term survival with these approaches.9PubMed Central. Treatment of Richter’s syndrome
These numbers are strikingly worse than outcomes for people who develop DLBCL without a prior history of CLL. One reason is that Richter transformation often occurs in patients who have already been treated for CLL, sometimes with multiple lines of therapy. Their bone marrow reserves may be depleted, their immune systems compromised, and their cancer may harbor mutations, like TP53 disruption, that confer resistance to conventional drugs. The biology of the transformed cells themselves also tends to be more aggressive than garden-variety DLBCL.
The Role of Stem Cell Transplantation
For patients who do respond to initial treatment and are physically fit enough, allogeneic stem cell transplantation (using donor cells) has been one of the few options that can produce durable remissions. A systematic review and meta-analysis found that allo-transplant yields encouraging overall survival in Richter syndrome, making it a reasonable option for patients whose disease responds to pre-transplant therapy.10PubMed Central. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis
The numbers, however, tell a more sobering story about the trade-offs involved. In a retrospective European study with a median follow-up of nearly seven years, three-year overall survival was about 39%, and three-year progression-free survival was 29%. Patients who were in complete remission at the time of transplant fared better, with a three-year progression-free survival of 39% compared to 21% for those who were not. But the procedure carries serious toxicity: non-relapse mortality reached 38% at three years, and over half the patients developed chronic graft-versus-host disease.11PubMed Central. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT This means the transplant itself accounts for a substantial share of deaths, a grim reminder that the treatment can be nearly as dangerous as the disease.
Targeted Therapies and Resistance
The revolution in targeted therapy for CLL, particularly BTK inhibitors like ibrutinib and BCL-2 inhibitors like venetoclax, has transformed how the underlying CLL is managed. But these drugs have a complicated relationship with Richter transformation. Some patients develop Richter syndrome while on these therapies, and in some cases the transformation appears to be driven by resistance mutations that arise under drug pressure. In a molecular analysis of such patients, resistance mutations in BTK (the target of ibrutinib) and BCL-2 (the target of venetoclax) were identified in patients who developed Richter transformation during treatment.12PubMed. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax
Whether targeted therapies for CLL actually increase the risk of transformation or whether they simply allow patients to live long enough for transformation to occur remains an open question. What is clear is that once Richter syndrome develops, the drugs that were keeping CLL in check are usually no longer effective against the aggressive lymphoma, and new treatment strategies are needed.
CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy, in which a patient’s own immune cells are re-engineered to attack cancer, has emerged as one of the more promising options for Richter transformation. A large international retrospective study reported an overall response rate of 63%, with 46% of patients achieving complete remission.13PubMed. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study A European multicenter analysis found similar response rates, with a median progression-free survival of 8 months overall and a much longer 31.6 months for patients who achieved complete remission within the first three months after treatment.14PubMed Central. CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia
CAR T-cell therapy is not without risks. Side effects include cytokine release syndrome, a potentially dangerous inflammatory reaction, and neurotoxicity. In the international study, roughly one in six patients experienced severe cytokine release syndrome, and over a third had significant neurotoxicity.13PubMed. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study But given how limited the alternatives are, these response rates represent a meaningful advance. The strong correlation between achieving early complete remission and durable benefit underscores the importance of response assessment in guiding follow-up care.
Bispecific Antibodies and Epcoritamab
Another emerging approach involves bispecific antibodies, molecules engineered to grab onto both a cancer cell and an immune cell simultaneously, forcing the immune system to attack the tumor. Epcoritamab, a bispecific antibody targeting CD3 on T cells and CD20 on tumor cells, has been tested specifically in Richter transformation patients through the EPCORE CLL-1 trial.
Primary results from this trial showed an overall response rate of about 48% across 42 patients, with responses running higher in patients receiving it as their first treatment for the transformation, reaching 57% in that group. For patients with TP53 abnormalities, widely considered the hardest-to-treat population, the response rate was 40%.15The Lancet Haematology. Subcutaneous epcoritamab in patients with Richter transformation (EPCORE CLL-1): primary results from a multicentre, open-label, phase 1b/2 trial Earlier data from the same trial reported that among patients who achieved complete remission, an estimated 53% remained in remission at nine months, with that figure climbing to 75% for those who had not previously been treated for their transformation.16Clinical Lymphoma Myeloma and Leukemia. Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial
What makes epcoritamab appealing beyond the numbers is its practical profile. It is given as a subcutaneous injection rather than an intravenous infusion, can be administered in an outpatient setting, and avoids the manufacturing delay required for CAR T cells. Cytokine release syndrome does occur but has generally been manageable. For older or less fit patients who may not tolerate the intensity of CAR T-cell therapy or transplant, this kind of off-the-shelf immunotherapy could fill an important gap.
Prognosis and Scoring Systems
Overall survival after Richter transformation remains poor, with median survival generally measured in months. Two prognostic scoring systems have been developed to help estimate where individual patients fall on this spectrum. The first, proposed in 2006, assigns points based on five features: poor physical performance status, elevated LDH (at least 1.5 times the upper limit of normal), low platelet count, large tumor size exceeding 5 cm, and having received more than one prior CLL treatment. Patients in the lowest-risk group had a median survival of about 1.1 years, while those in the highest-risk category survived a median of roughly five weeks.17Blood. How we treat Richter syndrome – Section: What is the prognosis of RS?
A second scoring system incorporates physical performance status, TP53 disruption, and response to initial treatment. Both systems underscore the same basic reality: patients who are already in poor shape, have high-risk genetics, and don’t respond to their first round of treatment face an extremely compressed timeline. On the other hand, the small subset who achieve a complete remission, particularly those whose transformation is clonally unrelated to their CLL, can sometimes enjoy remissions lasting years.
The Hodgkin Variant
The Hodgkin lymphoma variant of Richter transformation is rare enough that building strong evidence around it has been slow. But the data that do exist paint a notably different picture from the DLBCL type. In a large multicenter collaboration, patients with Hodgkin-type transformation who were treated with ABVD-based chemotherapy, the standard regimen for classical Hodgkin lymphoma, had a median overall survival of over 13 years.18Haematologica. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration A separate study found that achieving complete remission after ABVD was the single most important predictor of long-term survival for these patients.19PubMed. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma
These outcomes stand in stark contrast to DLBCL-type transformation. The Hodgkin variant still carries inferior outcomes compared to Hodgkin lymphoma arising in people without CLL, and there are specific concerns about managing it in patients who are on or have recently finished targeted CLL therapies.20PubMed Central. Hodgkin’s variant of Richter transformation during ibrutinib therapy: A case report and review of the literature But the overall message for patients diagnosed with this subtype is considerably more hopeful than for the DLBCL form.
Liquid Biopsy and Early Detection
One of the biggest frustrations with Richter transformation is that by the time symptoms appear and a biopsy confirms the diagnosis, the aggressive lymphoma has often already spread extensively. This is driving interest in blood-based approaches that could catch the transformation earlier. Novel profiling techniques, including cell-free DNA analysis of patient blood samples and single-cell sequencing of tumor tissue, are showing promise for identifying the molecular fingerprints of emerging transformation clones before they become clinically obvious.21PubMed Central. Richter syndrome: novel insights into the biology of transformation
This kind of noninvasive surveillance could be transformative in its own right. If high-risk CLL patients could be monitored with periodic blood tests that flag the earliest molecular signs of transformation, treatment could potentially begin when tumor burden is low, response rates might be higher, and the devastating clinical spiral that currently defines many Richter diagnoses might be partially averted. The technology is still in early stages, but it represents one of the more exciting directions in the field. For patients with CLL who carry high-risk features like TP53 mutations or unmutated IGHV genes, the possibility of proactive monitoring rather than waiting for symptoms is a meaningful shift in the clinical conversation.